(Alliance News) - AstraZeneca PLC on Wednesday said a US court decided in its favour in litigation over patents for its Symbicort asthma and obstructive pulmonary disease treatment.
The US District Court for the Northern District of West Virginia found in FTSE 100 drug maker Astra's favour in litigation against Mylan Pharmaceuticals Inc and Kindeva Drug Delivery LP. The court determined that asserted claims in three US Symbicort patents were not invalid.
Astra initiated its litigation against Mylan and then 3M Co in October 2018, claiming infringement of various US patents for Symbicort. Kindeva was added as a defendant in July 2020, while 3M was voluntarily dismissed from the case.
Ruud Dobber, executive vice president of Astra's BioPharmaceuticals Business Unit, said: "AstraZeneca is pleased with the court's decision, and we maintain full confidence in the strength of our intellectual property rights protecting Symbicort."
Shares in Astra were up 0.4% at 6,907.00 pence in London in early morning trading.
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)